Show simple item record

dc.contributor.authorAMCP Addiction Treatment Advisory Group
dc.contributor.authorLenz, Kimberly J.
dc.date2022-08-11T08:08:06.000
dc.date.accessioned2022-08-23T15:42:32Z
dc.date.available2022-08-23T15:42:32Z
dc.date.issued2016-12-20
dc.date.submitted2017-01-13
dc.identifier.citationAcademy of Managed Care Pharmacy. The Role of Managed Care Pharmacy in Improving Access to Naloxone: Findings from the AMCP Addiction Treatment Advisory Group. December 2016. http://bit.ly/2fJogY9
dc.identifier.urihttp://hdl.handle.net/20.500.14038/26872
dc.description.abstractKimberly Lenz, PharmD, a clinical pharmacy manager in the Office of Clinical Affairs, provided insight and expertise for this report as a member of the Academy of Managed Care Pharmacy's Addiction Treatment Advisory Group. The group's report identifies barriers to care and details how managed care organizations can better address the opioid addiction crisis, including improving access to naloxone and Medication Assisted Therapies (MAT) as well as ensuring benefit design will support alternative pain management methods.
dc.language.isoen_US
dc.relation.urlhttp://bit.ly/2fJogY9
dc.subjectBehavioral Health
dc.subjectOpioid Management
dc.subjectPharmacy
dc.subjectHealth Services Administration
dc.subjectHealth Services Research
dc.subjectPharmacy and Pharmaceutical Sciences
dc.subjectSubstance Abuse and Addiction
dc.titleThe Role of Managed Care Pharmacy in Improving Access to Naloxone: Findings from the AMCP Addiction Treatment Advisory Group
dc.typeReport
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/commed_pubs/11
dc.identifier.contextkey9545464
html.description.abstract<p>Kimberly Lenz, PharmD, a clinical pharmacy manager in the Office of Clinical Affairs, provided insight and expertise for this report as a member of the Academy of Managed Care Pharmacy's Addiction Treatment Advisory Group. The group's report identifies barriers to care and details how managed care organizations can better address the opioid addiction crisis, including improving access to naloxone and Medication Assisted Therapies (MAT) as well as ensuring benefit design will support alternative pain management methods.</p>
dc.identifier.submissionpathcommed_pubs/11
dc.contributor.departmentCommonwealth Medicine, Office of Clinical Affairs
dc.contributor.departmentCommonwealth Medicine, Center for Health Policy and Research


This item appears in the following Collection(s)

Show simple item record